Elin Borgen

  • Consultant; MD, PhD

ResearchGate - Elin Borgen

 

Publications 2026

Lien TG, Ohnstad HO, Lingjærde OC, Vallon-Christersson J, Aaserud M, Sveli MAT, Borg Å, On Behalf Of Osbreac, Garred Ø, Borgen E, Naume B, Russnes H, Sørlie T (2026)
Correction: Lien et al. Sample Preparation Approach Influences PAM50 Risk of Recurrence Score in Early Breast Cancer. Cancers 2021, 13, 6118
Cancers (Basel), 18 (9)
DOI 10.3390/cancers18091337, PubMed 42122291

Pladsen AV, Smebye ML, Garred Ø, Borgen E, Egeland EV, Haugen MH, Dahle MA, Prasmickaite L, Mælandsmo GM, Hovig E, Nakken S, Østgaard A, Bergheim IR, Reinertsen K, Ohnstad HO, Schlichting E, Skjerven HK, Dale AB, Wist E, Naume B, Russnes HG, Lingjærde OC, Engebraaten O (2026)
DNA-Based Biomarkers as Predictors of Carboplatin Response in Neoadjuvant Treatment for Hormone Receptor Positive and Triple-Negative Breast Cancer
Clin Cancer Res (in press)
DOI 10.1158/1078-0432.CCR-26-2212, PubMed 42870529

Publications 2025

Røssevold AH, Tekpli X, Lingjærde OC, Russnes HG, Vallon-Christersson J, Borgen E, Lømo J, Garred Ø, Dorraji E, Kristensen VN, Naume B, Kyte JA (2025)
High tumor expression of CTLA4 identifies lymph node-negative basal-like breast cancer patients with excellent prognosis
Commun Med (Lond), 5 (1), 234
DOI 10.1038/s43856-025-00865-z, PubMed 40523912

Publications 2024

Andresen NK, Røssevold AH, Borgen E, Schirmer CB, Gilje B, Garred Ø, Lømo J, Stensland M, Nordgård O, Falk RS, Mathiesen RR, Russnes HG, Kyte JA, Naume B (2024)
Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors - a biomarker analysis of the ALICE and ICON trials
Mol Oncol, 19 (7), 2092-2108
DOI 10.1002/1878-0261.13675, PubMed 38978352

Publications 2022

Dorraji E, Borgen E, Segura-Peña D, Rawat P, Smorodina E, Dunn C, Greiff V, Sekulić N, Russnes H, Kyte JA (2022)
Development of a High-Affinity Antibody against the Tumor-Specific and Hyperactive 611-p95HER2 Isoform
Cancers (Basel), 14 (19)
DOI 10.3390/cancers14194859, PubMed 36230782

Publications 2021

Engebraaten O, Yau C, Berg K, Borgen E, Garred Ø, Berstad MEB, Fremstedal ASV, DeMichele A, Veer LV', Esserman L, Weyergang A (2021)
RAB5A expression is a predictive biomarker for trastuzumab emtansine in breast cancer
Nat Commun, 12 (1), 6427
DOI 10.1038/s41467-021-26018-z, PubMed 34741021

Hartkopf AD, Brucker SY, Taran FA, Harbeck N, von Au A, Naume B, Pierga JY, Hoffmann O, Beckmann MW, Rydén L, Fehm T, Aft R, Solà M, Walter V, Rack B, Schuetz F, Borgen E, Ta MH, Bittner AK, Fasching PA, Fernö M, Krawczyk N, Weilbaecher K, Margelí M, Hahn M, Jueckstock J, Domschke C, Bidard FC, Kasimir-Bauer S, Schoenfisch B et al. (2021)
Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis
Eur J Cancer, 154, 128-137
DOI 10.1016/j.ejca.2021.06.028, PubMed 34265505

Haugen MH, Lingjærde OC, Hedenfalk I, Garred Ø, Borgen E, Loman N, Hatschek T, Børresen-Dale AL, Naume B, Mills GB, Mælandsmo GM, Engebraaten O (2021)
Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast Cancers
JCO Precis Oncol, 5
DOI 10.1200/PO.20.00086, PubMed 34036235

Hugenschmidt H, Labori KJ, Borgen E, Brunborg C, Schirmer CB, Seeberg LT, Naume B, Wiedswang G (2021)
Preoperative CTC-Detection by CellSearch® Is Associated with Early Distant Metastasis and Impaired Survival in Resected Pancreatic Cancer
Cancers (Basel), 13 (3)
DOI 10.3390/cancers13030485, PubMed 33513877

Krüger K, Silwal-Pandit L, Wik E, Straume O, Stefansson IM, Borgen E, Garred Ø, Naume B, Engebraaten O, Akslen LA (2021)
Baseline microvessel density predicts response to neoadjuvant bevacizumab treatment of locally advanced breast cancer
Sci Rep, 11 (1), 3388
DOI 10.1038/s41598-021-81914-0, PubMed 33564016

Lien TG, Ohnstad HO, Lingjærde OC, Vallon-Christersson J, Aaserud M, Sveli MAT, Borg Å, Osbreac OBO, Garred Ø, Borgen E, Naume B, Russnes H, Sørlie T (2021)
Sample Preparation Approach Influences PAM50 Risk of Recurrence Score in Early Breast Cancer
Cancers (Basel), 13 (23)
DOI 10.3390/cancers13236118, PubMed 34885228

Publications 2020

Helland T, Naume B, Hustad S, Bifulco E, Kvaløy JT, Saetersdal AB, Synnestvedt M, Lende TH, Gilje B, Mjaaland I, Weyde K, Blix ES, Wiedswang G, Borgen E, Hertz DL, Janssen EAM, Mellgren G, Søiland H (2020)
Low Z-4OHtam concentrations are associated with adverse clinical outcome among early stage premenopausal breast cancer patients treated with adjuvant tamoxifen
Mol Oncol, 15 (4), 957-967
DOI 10.1002/1878-0261.12865, PubMed 33252186

Hugenschmidt H, Labori KJ, Brunborg C, Verbeke CS, Seeberg LT, Bendigtsen Schirmer C, Renolen A, Borgen E, Naume B, Wiedswang G (2020)
Cytokeratin-positive cells in the bone marrow from patients with pancreatic, periampullary malignancy and benign pancreatic disease show no prognostic information
BMC Cancer, 20 (1), 1107
DOI 10.1186/s12885-020-07510-z, PubMed 33198661

Tinholt M, Stavik B, Tekpli X, Garred Ø, Borgen E, Kristensen V, Sahlberg KK, Sandset PM, Iversen N (2020)
Coagulation factor V is a marker of tumor-infiltrating immune cells in breast cancer
Oncoimmunology, 9 (1), 1824644
DOI 10.1080/2162402X.2020.1824644, PubMed 33457104

von der Lippe Gythfeldt H, Lien T, Tekpli X, Silwal-Pandit L, Borgen E, Garred Ø, Skjerven H, Schlichting E, Lundgren S, Wist E, Naume B, Kristensen V, Børresen-Dale AL, Lingjaerde OC, Engebraaten O (2020)
Immune phenotype of tumor microenvironment predicts response to bevacizumab in neoadjuvant treatment of ER-positive breast cancer
Int J Cancer, 147 (9), 2515-2525
DOI 10.1002/ijc.33108, PubMed 32488909

Publications 2019

Debik J, Euceda LR, Lundgren S, Gythfeldt HVL, Garred Ø, Borgen E, Engebraaten O, Bathen TF, Giskeødegård GF (2019)
Assessing Treatment Response and Prognosis by Serum and Tissue Metabolomics in Breast Cancer Patients
J Proteome Res, 18 (10), 3649-3660
DOI 10.1021/acs.jproteome.9b00316, PubMed 31483662

Johansson HJ, Socciarelli F, Vacanti NM, Haugen MH, Zhu Y, Siavelis I, Fernandez-Woodbridge A, Aure MR, Sennblad B, Vesterlund M, Branca RM, Orre LM, Huss M, Fredlund E, Beraki E, Garred Ø, Boekel J, Sauer T, Zhao W, Nord S, Höglander EK, Jans DC, Brismar H, Haukaas TH, Bathen TF, Schlichting E, Naume B, Consortia Oslo Breast Cancer Research Consortium (OSBREAC), Luders T, Borgen E et al. (2019)
Breast cancer quantitative proteome and proteogenomic landscape
Nat Commun, 10 (1), 1600
DOI 10.1038/s41467-019-09018-y, PubMed 30962452

Lai X, Geier OM, Fleischer T, Garred Ø, Borgen E, Funke SW, Kumar S, Rognes ME, Seierstad T, Børresen-Dale AL, Kristensen VN, Engebraaten O, Köhn-Luque A, Frigessi A (2019)
Toward Personalized Computer Simulation of Breast Cancer Treatment: A Multiscale Pharmacokinetic and Pharmacodynamic Model Informed by Multitype Patient Data
Cancer Res, 79 (16), 4293-4304
DOI 10.1158/0008-5472.CAN-18-1804, PubMed 31118201

Nome ME, Euceda LR, Jabeen S, Debik J, Bathen TF, Giskeødegård GF, Taskén KA, Maelandsmo GM, Halvorsen B, Yndestad A, Borgen E, Garred Ø, Aukrust P, Ueland T, Engebraaten O, Kristensen VN, Tekpli X (2019)
Serum levels of inflammation-related markers and metabolites predict response to neoadjuvant chemotherapy with and without bevacizumab in breast cancers
Int J Cancer, 146 (1), 223-235
DOI 10.1002/ijc.32638, PubMed 31444972

Tekpli X, Lien T, Røssevold AH, Nebdal D, Borgen E, Ohnstad HO, Kyte JA, Vallon-Christersson J, Fongaard M, Due EU, Svartdal LG, Sveli MAT, Garred Ø, OSBREAC, Frigessi A, Sahlberg KK, Sørlie T, Russnes HG, Naume B, Kristensen VN (2019)
An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment
Nat Commun, 10 (1), 5499
DOI 10.1038/s41467-019-13329-5, PubMed 31796750

Publications 2018

Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz JA, Hartkopf A, Generali D, Rothé F, Smerage J, Muinelo-Romay L, Stebbing J, Viens P, Magbanua MJM, Hall CS, Engebraaten O, Takata D, Vidal-Martínez J, Onstenk W, Fujisawa N, Diaz-Rubio E, Taran FA, Cappelletti MR, Ignatiadis M et al. (2018)
Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis
J Natl Cancer Inst, 110 (6), 560-567
DOI 10.1093/jnci/djy018, PubMed 29659933

Borgen E, Rypdal MC, Sosa MS, Renolen A, Schlichting E, Lønning PE, Synnestvedt M, Aguirre-Ghiso JA, Naume B (2018)
NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients
Breast Cancer Res, 20 (1), 120
DOI 10.1186/s13058-018-1049-0, PubMed 30322396

Höglander EK, Nord S, Wedge DC, Lingjærde OC, Silwal-Pandit L, Gythfeldt HV, Vollan HKM, Fleischer T, Krohn M, Schlitchting E, Borgen E, Garred Ø, Holmen MM, Wist E, Naume B, Van Loo P, Børresen-Dale AL, Engebraaten O, Kristensen V (2018)
Time series analysis of neoadjuvant chemotherapy and bevacizumab-treated breast carcinomas reveals a systemic shift in genomic aberrations
Genome Med, 10 (1), 92
DOI 10.1186/s13073-018-0601-y, PubMed 30497530

Publications 2017

Davies H, Morganella S, Purdie CA, Jang SJ, Borgen E, Russnes H, Glodzik D, Zou X, Viari A, Richardson AL, Børresen-Dale AL, Thompson A, Eyfjord JE, Kong G, Stratton MR, Nik-Zainal S (2017)
Whole-Genome Sequencing Reveals Breast Cancers with Mismatch Repair Deficiency
Cancer Res, 77 (18), 4755-4762
DOI 10.1158/0008-5472.CAN-17-1083, PubMed 28904067

Egeland EV, Boye K, Park D, Synnestvedt M, Sauer T, Oslo Breast Cancer Consortium (OSBREAC), Naume B, Borgen E, Mælandsmo GM (2017)
Prognostic significance of S100A4-expression and subcellular localization in early-stage breast cancer
Breast Cancer Res Treat, 162 (1), 127-137
DOI 10.1007/s10549-016-4096-1, PubMed 28058579

Euceda LR, Haukaas TH, Giskeodegard GF, Vettukattil R, Engel J, Silwal-Pandit L, Lundgren S, Borgen E, Garred O, Postma G, Buydens LMC, Borresen-Dale AL, Engebraaten O, Bathen TF (2017)
Evaluation of metabolomic changes during neoadjuvant chemotherapy combined with bevacizumab in breast cancer using MR spectroscopy
Metabolomics, 13 (4), 37
DOI 10.1007/s11306-017-1168-0

Fleischer T, Tekpli X, Mathelier A, Wang S, Nebdal D, Dhakal HP, Sahlberg KK, Schlichting E, Oslo Breast Cancer Research Consortium (OSBREAC), Børresen-Dale AL, Borgen E, Naume B, Eskeland R, Frigessi A, Tost J, Hurtado A, Kristensen VN (2017)
DNA methylation at enhancers identifies distinct breast cancer lineages
Nat Commun, 8 (1), 1379
DOI 10.1038/s41467-017-00510-x, PubMed 29123100

Helland T, Henne N, Bifulco E, Naume B, Borgen E, Kristensen VN, Kvaløy JT, Lash TL, Alnæs GIG, van Schaik RH, Janssen EAM, Hustad S, Lien EA, Mellgren G, Søiland H (2017)
Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients
Breast Cancer Res, 19 (1), 125
DOI 10.1186/s13058-017-0916-4, PubMed 29183390

Ohnstad HO, Borgen E, Falk RS, Lien TG, Aaserud M, Sveli MAT, Kyte JA, Kristensen VN, Geitvik GA, Schlichting E, Wist EA, Sørlie T, Russnes HG, Naume B (2017)
Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up
Breast Cancer Res, 19 (1), 120
DOI 10.1186/s13058-017-0911-9, PubMed 29137653

Seeberg LT, Brunborg C, Waage A, Hugenschmidt H, Renolen A, Stav I, Bjørnbeth BA, Borgen E, Naume B, Brudvik KW, Wiedswang G (2017)
Survival Impact of Primary Tumor Lymph Node Status and Circulating Tumor Cells in Patients with Colorectal Liver Metastases
Ann Surg Oncol, 24 (8), 2113-2121
DOI 10.1245/s10434-017-5818-2, PubMed 28258416

Silwal-Pandit L, Nord S, von der Lippe Gythfeldt H, Møller EK, Fleischer T, Rødland E, Krohn M, Borgen E, Garred Ø, Olsen T, Vu P, Skjerven H, Fangberget A, Holmen MM, Schlitchting E, Wille E, Nordberg Stokke M, Moen Vollan HK, Kristensen V, Langerød A, Lundgren S, Wist E, Naume B, Lingjærde OC, Børresen-Dale AL, Engebraaten O (2017)
The Longitudinal Transcriptional Response to Neoadjuvant Chemotherapy with and without Bevacizumab in Breast Cancer
Clin Cancer Res, 23 (16), 4662-4670
DOI 10.1158/1078-0432.CCR-17-0160, PubMed 28487444

Publications 2016

Demeulemeester J, Kumar P, Møller EK, Nord S, Wedge DC, Peterson A, Mathiesen RR, Fjelldal R, Zamani Esteki M, Theunis K, Fernandez Gallardo E, Grundstad AJ, Borgen E, Baumbusch LO, Børresen-Dale AL, White KP, Kristensen VN, Van Loo P, Voet T, Naume B (2016)
Tracing the origin of disseminated tumor cells in breast cancer using single-cell sequencing
Genome Biol, 17 (1), 250
DOI 10.1186/s13059-016-1109-7, PubMed 27931250

Publications 2015

Brudvik KW, Seeberg LT, Hugenschmidt H, Renolen A, Schirmer CB, Brunborg C, Bjørnbeth BA, Borgen E, Naume B, Waage A, Wiedswang G (2015)
Detection of Circulating Tumor Cells at Surgery and at Follow-Up Assessment to Predict Survival After Two-Stage Liver Resection of Colorectal Liver Metastases
Ann Surg Oncol, 22 (12), 4029-37
DOI 10.1245/s10434-015-4482-7, PubMed 25801354

Lund-Iversen M, Grøholt KK, Helland Å, Borgen E, Brustugun OT (2015)
NUT expression in primary lung tumours
Diagn Pathol, 10, 156
DOI 10.1186/s13000-015-0395-9, PubMed 26341600

Silwal-Pandit L, Russnes H, Borgen E, Skarpeteig V, Moen Vollan HK, Schlichting E, Kåresen R, Naume B, Børresen-Dale AL, Farnebo M, Langerød A (2015)
The Sub-Cellular Localization of WRAP53 Has Prognostic Impact in Breast Cancer
PLoS One, 10 (10), e0139965
DOI 10.1371/journal.pone.0139965, PubMed 26460974

Publications 2014

Fosså SD, Hess SL, Paus E, Borgen E (2014)
Circulating tumor cells in patients with metastatic castration resistant prostate cancer: exploratory findings at a tertiary referral hospital
Res Rep Urol, 6, 121-6
DOI 10.2147/RRU.S68477, PubMed 25328865

Gilje B, Nordgård O, Tjensvoll K, Borgen E, Synnestvedt M, Smaaland R, Naume B (2014)
Comparison of molecular and immunocytochemical methods for detection of disseminated tumor cells in bone marrow from early breast cancer patients
BMC Cancer, 14, 514
DOI 10.1186/1471-2407-14-514, PubMed 25023626

Ignatiadis M, Riethdorf S, Bidard FC, Vaucher I, Khazour M, Rothé F, Metallo J, Rouas G, Payne RE, Coombes R, Teufel I, Andergassen U, Apostolaki S, Politaki E, Mavroudis D, Bessi S, Pestrin M, Di Leo A, Campion M, Reinholz M, Perez E, Piccart M, Borgen E, Naume B, Jimenez J, Aura C, Zorzino L, Cassatella M, Sandri M, Mostert B et al. (2014)
International study on inter-reader variability for circulating tumor cells in breast cancer
Breast Cancer Res, 16 (2), R43
DOI 10.1186/bcr3647, PubMed 24758318

Naume B, Synnestvedt M, Falk RS, Wiedswang G, Weyde K, Risberg T, Kersten C, Mjaaland I, Vindi L, Sommer HH, Sætersdal AB, Rypdal MC, Bendigtsen Schirmer C, Wist EA, Borgen E (2014)
Clinical outcome with correlation to disseminated tumor cell (DTC) status after DTC-guided secondary adjuvant treatment with docetaxel in early breast cancer
J Clin Oncol, 32 (34), 3848-57
DOI 10.1200/JCO.2014.56.9327, PubMed 25366688

Nilsen LB, Fangberget A, Geier OM, Engebraaten O, Borgen E, Olsen DR, Seierstad T (2014)
Associations between tumor vascularization assessed by in vivo DCE-MRI and the presence of disseminated tumor cells in bone marrow in breast cancer patients at the time of diagnosis
J Magn Reson Imaging, 40 (6), 1382-91
DOI 10.1002/jmri.24502, PubMed 24470360

Publications 2013

Mikalsen LT, Dhakal HP, Bruland ØS, Naume B, Borgen E, Nesland JM, Olsen DR (2013)
The clinical impact of mean vessel size and solidity in breast carcinoma patients
PLoS One, 8 (10), e75954
DOI 10.1371/journal.pone.0075954, PubMed 24146798

Møller EK, Kumar P, Voet T, Peterson A, Van Loo P, Mathiesen RR, Fjelldal R, Grundstad J, Borgen E, Baumbusch LO, Naume B, Børresen-Dale AL, White KP, Nord S, Kristensen VN (2013)
Next-generation sequencing of disseminated tumor cells
Front Oncol, 3, 320
DOI 10.3389/fonc.2013.00320, PubMed 24427740

Publications 2012

Dhakal HP, Naume B, Synnestvedt M, Borgen E, Kaaresen R, Schlichting E, Wiedswang G, Bassarova A, Holm R, Giercksky KE, Nesland JM (2012)
Expression of vascular endothelial growth factor and vascular endothelial growth factor receptors 1 and 2 in invasive breast carcinoma: prognostic significance and relationship with markers for aggressiveness
Histopathology, 61 (3), 350-64
DOI 10.1111/j.1365-2559.2012.04223.x, PubMed 22690749

Dhakal HP, Naume B, Synnestvedt M, Borgen E, Kaaresen R, Schlichting E, Wiedswang G, Bassarova A, Holm R, Giercksky KE, Nesland JM (2012)
Expression of cyclooxygenase-2 in invasive breast carcinomas and its prognostic impact
Histol Histopathol, 27 (10), 1315-25
DOI 10.14670/HH-27.1315, PubMed 22936450

Mathiesen RR, Borgen E, Renolen A, Løkkevik E, Nesland JM, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, Kvalheim G, Lønning PE, Naume B (2012)
Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival
Breast Cancer Res, 14 (4), R117
DOI 10.1186/bcr3242, PubMed 22889108

Synnestvedt M, Borgen E, Russnes HG, Kumar NT, Schlichting E, Giercksky KE, Kåresen R, Nesland JM, Naume B (2012)
Combined analysis of vascular invasion, grade, HER2 and Ki67 expression identifies early breast cancer patients with questionable benefit of systemic adjuvant therapy
Acta Oncol, 52 (1), 91-101
DOI 10.3109/0284186X.2012.713508, PubMed 22934555

Synnestvedt M, Borgen E, Wist E, Wiedswang G, Weyde K, Risberg T, Kersten C, Mjaaland I, Vindi L, Schirmer C, Nesland JM, Naume B (2012)
Disseminated tumor cells as selection marker and monitoring tool for secondary adjuvant treatment in early breast cancer. Descriptive results from an intervention study
BMC Cancer, 12, 616
DOI 10.1186/1471-2407-12-616, PubMed 23259667

Publications 2011

Janni W, Vogl FD, Wiedswang G, Synnestvedt M, Fehm T, Jückstock J, Borgen E, Rack B, Braun S, Sommer H, Solomayer E, Pantel K, Nesland J, Friese K, Naume B (2011)
Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse--a European pooled analysis
Clin Cancer Res, 17 (9), 2967-76
DOI 10.1158/1078-0432.CCR-10-2515, PubMed 21415211

Mathiesen RR, Fjelldal R, Liestøl K, Due EU, Geigl JB, Riethdorf S, Borgen E, Rye IH, Schneider IJ, Obenauf AC, Mauermann O, Nilsen G, Christian Lingjaerde O, Børresen-Dale AL, Pantel K, Speicher MR, Naume B, Baumbusch LO (2011)
High-resolution analyses of copy number changes in disseminated tumor cells of patients with breast cancer
Int J Cancer, 131 (4), E405-15
DOI 10.1002/ijc.26444, PubMed 21935921

Molloy TJ, Bosma AJ, Baumbusch LO, Synnestvedt M, Borgen E, Russnes HG, Schlichting E, van't Veer LJ, Naume B (2011)
The prognostic significance of tumour cell detection in the peripheral blood versus the bone marrow in 733 early-stage breast cancer patients
Breast Cancer Res, 13 (3), R61
DOI 10.1186/bcr2898, PubMed 21672237

Publications 2010

Effenberger KE, Borgen E, Eulenburg CZ, Bartkowiak K, Grosser A, Synnestvedt M, Kaaresen R, Brandt B, Nesland JM, Pantel K, Naume B (2010)
Detection and clinical relevance of early disseminated breast cancer cells depend on their cytokeratin expression pattern
Breast Cancer Res Treat, 125 (3), 729-38
DOI 10.1007/s10549-010-0911-2, PubMed 20449649

Naume B, Zhao X, Synnestvedt M, Borgen E, Russnes HG, Lingjaerde OC, Stromberg M, Wiedswang G, Kvalheim G, Karesen R, Nesland JM, Borresen-Dale AL, Sorlie T (2010)
Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer (vol 1, pg 160, 2007)
Mol. Oncol., 4 (2), 169
DOI 10.1016/j.molonc.2010.01.003

Russnes HG, Vollan HKM, Lingjærde OC, Krasnitz A, Lundin P, Naume B, Sørlie T, Borgen E, Rye IH, Langerød A, Chin SF, Teschendorff AE, Stephens PJ, Månér S, Schlichting E, Baumbusch LO, Kåresen R, Stratton MP, Wigler M, Caldas C, Zetterberg A, Hicks J, Børresen-Dale AL (2010)
Genomic architecture characterizes tumor progression paths and fate in breast cancer patients
Sci Transl Med, 2 (38), 38ra47
DOI 10.1126/scitranslmed.3000611, PubMed 20592421

Stakenborg T, Liu C, Henry O, Borgen E, Laddach N, Roeser T, Ritzi-Lehnert M, Fermér C, Hauch S, O'Sullivan CK, Lagae L (2010)
Automated genotyping of circulating tumor cells
Expert Rev Mol Diagn, 10 (6), 723-9
DOI 10.1586/erm.10.66, PubMed 20843197

Stakenborg T, Liu C, Henry O, O'Sullivan CK, Fermer C, Roeser T, Ritzi-Lehnert M, Hauch S, Borgen E, Laddach N, Lagae L (2010)
Lab-on-a-chip for the isolation and characterization of circulating tumor cells
Annu Int Conf IEEE Eng Med Biol Soc, 2010, 292-4
DOI 10.1109/IEMBS.2010.5627655, PubMed 21096963

Publications 2009

Dhakal HP, Bassarova A, Naume B, Synnestvedt M, Borgen E, Kaaresen R, Schlichting E, Wiedswang G, Giercksky KE, Nesland JM (2009)
Breast carcinoma vascularity: a comparison of manual microvessel count and Chalkley count
Histol Histopathol, 24 (8), 1049-59
DOI 10.14670/HH-24.1049, PubMed 19554512

Publications 2008

Dhakal HP, Naume B, Synnestvedt M, Borgen E, Kaaresen R, Schlichting E, Wiedswang G, Bassarova A, Giercksky KE, Nesland JM (2008)
Vascularization in primary breast carcinomas: its prognostic significance and relationship with tumor cell dissemination
Clin Cancer Res, 14 (8), 2341-50
DOI 10.1158/1078-0432.CCR-07-4214, PubMed 18413823

Publications 2007

Naume B, Zhao X, Synnestvedt M, Borgen E, Russnes HG, Lingjaerde OC, Strømberg M, Wiedswang G, Kvalheim G, Kåresen R, Nesland JM, Børresen-Dale AL, Sørlie T (2007)
Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer
Mol Oncol, 1 (2), 160-71
DOI 10.1016/j.molonc.2007.03.004, PubMed 19383292

Roeser T, Ritzi M, Drese KS, Laureyn W, Liu C, O'Sullivan CK, Ozalp VC, Fermer C, Nilsson O, Hauch S, Albert W, Borgen E, Nygre AO (2007)
Lab-on-chip for the isolation and characterization of circulating tumor cells
Annu Int Conf IEEE Eng Med Biol Soc, 2007, 6447-9
DOI 10.1109/IEMBS.2007.4353833, PubMed 18003499

Publications 2006

Fehm T, Braun S, Muller V, Janni W, Gebauer G, Marth C, Schindlbeck C, Wallwiener D, Borgen E, Naume B, Pantel K, Solomayer E (2006)
A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation
Cancer, 107 (5), 885-92
DOI 10.1002/cncr.22076, PubMed 16874814

Wiedswang G, Borgen E, Schirmer C, Kåresen R, Kvalheim G, Nesland JM, Naume B (2006)
Comparison of the clinical significance of occult tumor cells in blood and bone marrow in breast cancer
Int J Cancer, 118 (8), 2013-9
DOI 10.1002/ijc.21576, PubMed 16287086

Publications 2005

Furre IE, Shahzidi S, Luksiene Z, Møller MT, Borgen E, Morgan J, Tkacz-Stachowska K, Nesland JM, Peng Q (2005)
Targeting PBR by hexaminolevulinate-mediated photodynamic therapy induces apoptosis through translocation of apoptosis-inducing factor in human leukemia cells
Cancer Res, 65 (23), 11051-60
DOI 10.1158/0008-5472.CAN-05-0510, PubMed 16322255

Publications 2004

Naume B, Wiedswang G, Borgen E, Kvalheim G, Kåresen R, Qvist H, Janbu J, Harbitz T, Nesland JM (2004)
The prognostic value of isolated tumor cells in bone marrow in breast cancer patients: evaluation of morphological categories and the number of clinically significant cells
Clin Cancer Res, 10 (9), 3091-7
DOI 10.1158/1078-0432.ccr-03-0373, PubMed 15131048

Suo Z, Daehli KU, Lindboe CF, Borgen E, Bassarova A, Nesland JM (2004)
Real-time PCR quantification of c-erbB-2 gene is an alternative for FISH in the clinical management of breast carcinoma patients
Int J Surg Pathol, 12 (4), 311-8
DOI 10.1177/106689690401200404, PubMed 15494857

Wiedswang G, Borgen E, Kåresen R, Qvist H, Janbu J, Kvalheim G, Nesland JM, Naume B (2004)
Isolated tumor cells in bone marrow three years after diagnosis in disease-free breast cancer patients predict unfavorable clinical outcome
Clin Cancer Res, 10 (16), 5342-8
DOI 10.1158/1078-0432.CCR-04-0245, PubMed 15328170